At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
In Brief
A Phase 2 clinical trial evaluating Prasinezumab and Placebo for Parkinsons Disease. Active but no longer recruiting, targeting 586 participants across 110 sites in 9 countries.
Signals
Detailed Summary
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.
Study Details
Timeline
Arms & Interventions
Participants will receive an IV infusion of prasinezumab every 4 weeks (Q4W). Participants will enter into the optional Open Label Extension (OLE) once the double-blind treatment period has completed.
Participants will receive placebo as an IV infusion Q4W.
Interventions
Prasinezumab will be administered as an IV infusion to participants Q4W.
Prasinezumab placebo will be administered to participants.